Alyeska Investment Group
TARS icon

Alyeska Investment Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Alyeska Investment Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-75,000
Closed -$1.09M – 488
2022
Q2 		$1.09M Buy
+75,000
New +$1.13M 0.01% 458

Other funds holding TARS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group's TARS Position: Q3 2022 in Review

Alyeska Investment Group sold out of Tarsus Pharmaceuticals (TARS) in Q3 2022, closing a stake of 75,000 shares — an estimated $1.09M sold.

Alyeska Investment Group first reported a position in TARS in Q2 2022 and held it in 1 quarter. The position peaked at $1.09M in Q2 2022. 75 funds tracked by Wall St. Rank hold TARS as of Q3 2022.

  • Alyeska Investment Group reported no remaining Tarsus Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Alyeska Investment Group sold 75,000 Tarsus Pharmaceuticals shares in Q3 2022, an estimated $1.09M.
  • Alyeska Investment Group first reported a position in Tarsus Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Alyeska Investment Group's Tarsus Pharmaceuticals position peaked at $1.09M in Q2 2022.
  • 75 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2022.

Based on Alyeska Investment Group's 13F filing for Q3 2022, filed 14 Nov 2022.